Health Economic Evaluations

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

Is cancer quietly draining productivity across Asia‑Pacific? 💼📉 This analysis highlights large productivity losses driven by late diagnosis, unequal access to treatment, and weak return‑to‑work support — with sharp disparities between countries and industries. Tackling screening, survivorship care and employer‑led reintegration could recover economic value and improve patient outcomes. Read the full article for country comparisons and practical policy and employer actions. #SyenzaNews #oncology #HealthEconomics #healthcarepolicy #resourceallocation

Could counselling plus modest incentives be the missing piece to improving TB treatment adherence? New evidence shows that targeted counselling combined with small financial or non-financial incentives significantly raises treatment completion and cuts default rates, offering a practical, cost-effective option for TB programmes. The findings point to clear implementation and policy steps that can boost outcomes and reduce transmission. Read the full article to see the data, implementation tips, and the economic case for scale-up. 🔍 #SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #costeffectiveness

🌟 How are Merck's advancements in oncology reshaping cancer treatment? With significant new data set to be unveiled at ASCO 2026, Merck is enhancing treatment options for cancers like melanoma and lung cancer, demonstrating long-term survival benefits through innovative therapy combinations. Dive into the insights from their presentations and discover how these breakthroughs could impact patient care. #SyenzaNews #oncology #drugdevelopment #HealthcareInnovation

Could marstacimab reshape hemophilia care in Portugal? 📊 A new cost‑effectiveness analysis models marstacimab versus standard prophylaxis and finds it may deliver better bleed prevention and quality‑adjusted life‑years at an acceptable incremental cost, with meaningful implications for budget impact and reimbursement decisions. The results give payers, clinicians, and policymakers clearer evidence to inform market access strategies. Read the full analysis to review the assumptions, sensitivity checks, and what this could mean for patients and the health system. #SyenzaNews #HealthEconomics #pharmaceuticals #costeffectiveness #Economicevaluation

Could NICE's endorsement of pembrolizumab reshape care for resectable head and neck cancer? 🧬 NICE now recommends adjuvant pembrolizumab for patients at high risk of recurrence, signaling a move to bring immunotherapy into earlier treatment stages and impacting clinical pathways, reimbursement, and access across the UK. Learn what this means for surgeons, oncologists, payers, and patients. Read the full analysis for eligibility details, expected clinical impact, and market access implications. #SyenzaNews #oncology #pharmaceuticals #MarketAccess #healthcarepolicy

Are your clinical studies ready for EU-wide HTA alignment? The European Commission has opened the first 2026 submission window for Joint Scientific Consultations (Jan 7–Feb 4, 2026) — a free opportunity to get early HTA input (including parallel EMA coordination) that helps design studies fit for Joint Clinical Assessments and smoother market access. Aligning evidence early can cut duplication, reduce assessment delays, and strengthen reimbursement cases. Read the full article to see key deadlines, submission steps, and practical tips to make the most of JSCs. 🔗 #SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬 NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding improved event‑free and overall survival versus blinatumomab, inotuzumab and ponatinib and cost‑effectiveness within NHS thresholds — though it’s not recommended for 18–25s due to pricing vs tisagenlecleucel. Read the full guidance to see what this means for clinicians, payers and developers. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Can health be a nation's most strategic asset? 💡📈 EFPIA’s guest analysis reframes health spending as high-return investment—showing how targeted innovation and earlier care (notably for HER2+ breast cancer) can reduce disease-driven productivity losses, unlock trillions in GDP, and deliver up to $4 back per $1 spent. It also outlines HEOR methods and policy shifts needed to make health central to economic strategy. Read the full article to explore the projections, methodology, and practical steps for policymakers and payers. #SyenzaNews #HealthEconomics #oncology #healthcarepolicy #innovation

🤔 Is the traditional QALY framework holding back the future of health technology assessment? A recent report from the Health Economics Methods Advisory (HEMA) group suggests it's time for a paradigm shift! By adopting a principled framework that includes novel value elements, organizations like NICE and ICER can enhance fairness in resource allocation in healthcare systems. Curious about how these changes could promote equitable health solutions? Dive deeper into the article to explore innovative approaches redefining economic evaluations in health technology. #SyenzaNews #HealthEconomics #CostEffectiveness #ResourceAllocation

🤔 How can we ensure that health technology truly delivers value? The latest **NICE HealthTech Methods Update** provides vital insights into refining how we evaluate health technologies, focusing on stakeholder engagement, economic analysis, and addressing health inequalities. These updates promise to enhance the transparency and relevance of evaluations, ultimately supporting more informed and equitable decisions in health systems. Dive deeper into these advancements and discover how they may shape the future of health technology assessment! #SyenzaNews #HealthTech #HealthEconomics #MarketAccess

🌍 Are we truly ready to adapt global health technology assessments to local realities? The latest article from NICE explores how their evidence-based health policy initiatives are shaping access and value for healthcare systems in lower and middle-income countries. However, it raises critical questions about the adaptability of their methods amidst diverse sociopolitical landscapes. Jump into the complexities of health technology assessments and the need for localized solutions. #SyenzaNews #HealthEconomics #GlobalHealth #HealthcarePolicy